NBTX

Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.